First Trust Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

First Trust Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-256,426	Closed	-$2.59M	–	359
2022 Q4	$2.59M	Buy	256,426 +27,827	+12%	+$278K	0.14%	198
2022 Q3	$2.27M	Buy	+228,599	New	+$2.26M	0.11%	242

First Trust Capital Management's EBAC Position: Q1 2023 in Review

First Trust Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 256,426 shares — an estimated $2.59M sold.

First Trust Capital Management first reported a position in EBAC in Q3 2022 and held it in 2 quarters. The position peaked at $2.59M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

First Trust Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
First Trust Capital Management sold 256,426 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $2.59M.
First Trust Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2022 and held it in 2 quarters.
First Trust Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $2.59M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on First Trust Capital Management's 13F filing for Q1 2023, filed 12 May 2023.